List of Daliresp drug patents
Daliresp is owned by Astrazeneca.
Daliresp contains Roflumilast.
Daliresp has a total of 5 drug patents out of which 0 drug patents have expired.
Daliresp was authorised for market use on 28 February, 2011.
Daliresp is available in tablet;oral dosage forms.
Daliresp can be used as treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations.
The generics of Daliresp are possible to be released after 08 March, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(13 days from now) | |
| US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(13 days from now) | |
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 1 month from now) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 1 month from now) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 1 month from now) | |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 28 February, 2011
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic